Dr. Kevin Harrington, Phd of the Royal Marsden Hospital, The Institute of Cancer Research, London, is the author of this…
Browsing:
Sarbajit Mukherjee, MD, MS, Assistant Professor, Roswell Park Comprehensive Cancer Center conducted a study to investigate the efficacy of a…
Prithvi Bose, an associate professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, focuses on…
In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the…
Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital Sunvozertinib established itself as the leading targeted therapy for NSCLC…
Nicholas Robert, MD – Chief Medical Officer of Ontada Nicholas J. Robert, the chief medical officer at Ontada, is responsible…
Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD,…
Lung Cancer Trials: Insights into Latest Clinical Trials in Thoracic Oncology – Expert Analysis from Ravi Salgia, MD By Ravi…
Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re…
iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the…
Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in…
Momelotinib Shows Promising JAK and ALK2 Inhabitation in Patients With Anemic Myelofibrosis: MOMENTUM Study It’s my pleasure today to discuss…
Srdan Verstovsek, MD, Ph.D., Professor, Department of Leukemia at MD Anderson Cancer Center. In this video, he speaks about Sierra…